Efficacy of Blood Pressure reduction of Losartan in selected Thai populations using Home Blood Pressure Monitoring and Office Blood Pressure measurements
Sarana Boonbaichaiyapruck, Wirunsiri Mekwiwatanawong, Kanuengnit Srisala,Montawatt Amnueypol, Prasit Keesukphan
22 September 2015
September 2015, 23:3
1.Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–23.
2.Aekplakorn W et al. Prevalence and Managment of prehypertension and hypertension by geographic regions of Thailand: the Third National Health Examination Survey, 2004. Journal of Hypertension 2008; 26(2): 191–198.
3.Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med 2004;15:348–57.
4.Myers MG. Current status of ambulatory blood pressure monitoring. Can J Cardiol 2004;20:1424–28.
5.Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of “masked hypertension” detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004;291:1342–49.
6.O’Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003;21:821–48.
7.Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72.
8.National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. CG127. 2011 http://guidance.nice.org.uk/CG127.
9.Mengden T et al. Self-measurement of blood pressure improves the accuracy and reduces the number of subjects in clinical trials. J Hypertens 1991; 9(suppl 6):S336–S337.
10.Sangwatanaroj S, Lertsuwunseri V. A Randomized Controlled Trial of the Effect of hypertensive educational program on Home Blood Pressure in Hypertensive Patients at King Chulalongkorn Hospital. Thai Heart J 2011;24:19–25.
11.Bobrie G et al. Duration of action of two ACE inhibitors using self blood pressure measurement. Thérapie 1997;52:187–93.
12.Timmermann PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999; 22: 147–53.
13.Dahlöf B, Devereux RB, Kjeldsen SE, et al. for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
14.Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–69.